Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

75.03EUR
11:38am EST
Change (% chg)

€1.45 (+1.97%)
Prev Close
€73.58
Open
€73.30
Day's High
€75.03
Day's Low
€73.30
Volume
2,708,681
Avg. Vol
2,037,087
52-wk High
€92.97
52-wk Low
€72.63

Latest Key Developments (Source: Significant Developments)

Sanofi files suit in U.S. to defend patent rights on Lantus
Tuesday, 8 Aug 2017 03:32pm EDT 

Aug 8 (Reuters) - Sanofi SA ::Sanofi files suit in the U.S. to defend its patent rights on Lantus.Says ‍filed a patent infringement suit against Merck Sharp & Dohme Corp​.Says ‍in its suit co alleges infringement of two patents​.  Full Article

Sanofi files suit in U.S. to defend patent rights on Lantus
Tuesday, 8 Aug 2017 03:31pm EDT 

Aug 8 (Reuters) - SANOFI ::REG-SANOFI FILES SUIT IN THE U.S. TO DEFEND ITS PATENT RIGHTS ON LANTUS.‍ANNOUNCED THAT IT FILED A PATENT INFRINGEMENT SUIT AGAINST MERCK SHARP & DOHME CORP. ("MERCK") ON AUGUST 8, 2017 IN UNITED STATES DISTRICT COURT FOR DISTRICT OF NEW JERSEY.IN ITS SUIT SANOFI ALLEGES INFRINGEMENT OF TWO PATENTS.​.  Full Article

Regeneron Q2 non-gaap earnings per share $4.17
Thursday, 3 Aug 2017 06:30am EDT 

Aug 3 (Reuters) - Regeneron Pharmaceuticals Inc :Regeneron reports second quarter 2017 financial and operating results.Q2 non-gaap earnings per share $4.17.Q2 earnings per share view $3.17 -- Thomson Reuters I/B/E/S.Sees 2017 eylea u.s. Net product sales approximately 10% growth over 2016.Sees 2017 capital expenditures $250 million - $285 million.Regeneron pharmaceuticals inc - qtrly ‍total revenues $1,470 million versus $1,213​ million.Regeneron pharmaceuticals inc - ‍raised estimated full year 2017 eylea u.s. Net sales growth guidance to approximately 10% over 2016​.Regeneron pharmaceuticals inc says q2 2017 eylea(®) (aflibercept) injection u.s. Net sales increased 11% to $919 million versus q2 2016.Q2 revenue view $1.35 billion -- Thomson Reuters I/B/E/S.Q2 gaap earnings per share $3.34.Regeneron pharmaceuticals inc - in q2, global net sales of praluent were $46 million, compared to $24 million in the second quarter of 2016‍​.Regeneron pharmaceuticals inc - sees fy ‍sanofi reimbursement of regeneron commercialization-related expenses to be $370 million - $400 million​.  Full Article

Sanofi genzyme says PEI Pharmacare has added Lemtrada to pharmacare formulary
Tuesday, 1 Aug 2017 12:27pm EDT 

Aug 1 (Reuters) - Sanofi Genzyme :Sanofi Genzyme says PEI Pharmacare has added Lemtrada to pharmacare formulary.  Full Article

Sanofi strengthens relationship with Evidation Health
Tuesday, 1 Aug 2017 08:11am EDT 

Aug 1 (Reuters) - SANOFI ::SAID ON MONDAY IT STRENGTHENS RELATIONSHIP WITH EVIDATION HEALTH.  Full Article

Lexicon Pharmaceuticals reports opt-in decision for U.S. co-promotion of sotagliflozin with Sanofi in type 1 diabetes
Monday, 31 Jul 2017 06:01pm EDT 

July 31 (Reuters) - Lexicon Pharmaceuticals Inc ::Lexicon Pharmaceuticals announces opt-in decision for u.s. Co-Promotion of sotagliflozin with Sanofi in type 1 diabetes.Lexicon Pharmaceuticals - says ‍Sanofi intends to file applications in first half of 2018 for EU and U.S. Regulatory reviews of sotagliflozin​.Lexicon Pharmaceuticals- ‍opt-in decision based on positive data from 3 phase 3 studies, intandem1, intandem2, intandem3​.  Full Article

Sanofi raises FY 2017 business EPS guidance to broadly stable at CER
Monday, 31 Jul 2017 07:30am EDT 

July 31 (Reuters) - Sanofi Sa :Sanofi raises FY 2017 business EPS guidance to broadly stable at CER.  Full Article

EU Medicines Agency recommends approval of Novartis' leukaemia drug
Friday, 21 Jul 2017 07:37am EDT 

July 21 (Reuters) - EU Medicines Agency: :EU Medicines Agency recommendations For July 2017.EU Medicines Agency recommends approval of Pfizer Inc and Merck KGAA Avelumab drug for cell carcinoma‍​.EU Medicines Agency recommends approval of Sanofi and Regeneron Dupixent drug for severe eczema.EU Medicines Agency recommends approval Of Roche Tecentriq drug for drug for bladder and lung cancer‍​.EU Medicines Agency recommends approval Of Advanced Accelerator Applications Lutathera drug for gastroenteropancreatic neuroendocrine tumours.EU Medicines Agency recommends against approval of Nektar Therapeutics and Daiichi Sankyo Onzeald drug for breast cancer.EU Medicines Agency recommends approval of Novartis Rydapt drug for leukaemia.  Full Article

Ablynx and Sanofi enter into a strategic collaboration
Thursday, 20 Jul 2017 01:13am EDT 

July 20 (Reuters) - ABLYNX NV : :ABLYNX AND SANOFI ENTER INTO A STRATEGIC COLLABORATION TO DEVELOP NANOBODY PRODUCT CANDIDATES FOCUSED ON IMMUNE-MEDIATED INFLAMMATORY DISEASES.ABLYNX NV - ‍COLLABORATION GIVES SANOFI ACCESS TO CERTAIN NANOBODIES IN ABLYNX'S EXISTING PORTFOLIO​.ABLYNX NV - ‍SANOFI GAINS EXCLUSIVE GLOBAL RIGHTS TO CERTAIN MULTI-SPECIFIC NANOBODIES AGAINST SELECTED TARGETS​.ABLYNX NV - ‍FINANCIAL TERMS INCLUDE AN UPFRONT PAYMENT OF EUR 23 MILLION TO ABLYNX​.ABLYNX NV - ‍ABLYNX WILL RECEIVE RESEARCH FUNDING, ESTIMATED TO AMOUNT TO EUR 8 MILLION FOR INITIALLY SELECTED TARGETS​.  Full Article

Emergent Biosolutions updates terms of termination of agreement related to acquisition of Sanofi's acam2000 business
Friday, 14 Jul 2017 07:28am EDT 

July 14 (Reuters) - Emergent Biosolutions Inc ::Emergent Biosolutions updates on terms of any termination of agreement related to acquisition of acam2000 business from Sanofi.Emergent Biosolutions - agreement will become void and have no effect, except that certain specified obligations of Emergent and Sanofi shall survive.Emergent Biosolutions - certain specified obligations of both parties shall survive including those concerning confidentiality and public announcements.  Full Article

Sanofi investors hungry for drug progress and deal news

PARIS, Dec 12 Sanofi still needs to convince markets it can deliver on an exciting and sustainable growth path as it contends with fresh difficulties in its vaccines arm and looks set for another gloomy year in diabetes, investors told Reuters.